ISRCTN71619711已完成不适用
Single-blind randomised controlled phase 1b trial of the safety and immunogenicity of lyophilised recombinant precipitated tropical malaria vaccine (BK-SE36) in Uganda
The Research Foundation for Microbial Diseases of Osaka University (BIKEN) (Japan)0 个研究点目标入组 140 人开始时间: 2009年4月8日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 140
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Inclusion criteria for Stage 1: 21 to 40 years old
- •Healthy subjects are specified, and the inclusion criteria of malnutrition index and laboratory test values were included to reduce individual variation.
- •1.1. Healthy adults; Ugandan males and females aged 21 to 40 years (age on informed consent)
- •1.2. Those who do not suffer from severe malnutrition (defined as an adult whose weight-for-height is below -3 standard deviation or less than 70% of the median of the National Center for Health Statistics [NCHS]/World Health Organization [WHO] normalised reference values)
- •1.3. Those who are able to agree, comply with matters to be observed during participation in the trial, undergo consultation/examination, as described in this protocol, and report symptoms
- •1.4. Those who are considered to be eligible to participate in this trial based on screening:
- •1.4.1. Vital signs and physical examination are within baseline range
- •1.4.2. Haematology within 25% deviations from the upper and lower limits of the baseline range. The differential white blood count is not questioned when the white blood cell count is within the baseline range.
- •1.4.3. Blood chemistry:
- •i. Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and creatinine within the baseline range
- •ii. Total bilirubin within 50% deviation from the upper limit
- •iii. Serum electrolytes within the baseline range
- •iv. Other blood chemistry items within 25% deviation from the upper and lower limits of the baseline range
- •1.4.4. Urinalysis within the normal range
- •2. Inclusion criteria for Stage 2: 6 to 20 years old
- •2.1. Healthy volunteers, irrespective of gender, aged 6 to 20 years (age on informed consent)
- •2.2. Those who do not suffer from severe malnutrition (defined as a child or adult whose weight-for-height is below -3 standard deviation or less than 70% of the median of the NCHS/WHO normalised reference values)
- •2.3. Those who can give affirmative agreement to participate in the trial. For children between 8 to 17 years, the child's assent takes precedence over the parent(s)/guardian(s) consent
- •2.4. Those who are able to agree, comply with matters to be observed during participation in the trial, undergo consultation/examination, as described in this protocol and report symptoms
- •2.5. Those who are considered to be eligible to participate in this trial based on screening:
- •2.5.1. Vital signs and physical examination are within baseline range
- •2.5.2. Hematology within 25% deviations from the upper and lower limits of the baseline range. The differential white blood count is not questioned when the white blood cell count is within the baseline range.
- •2.5.3. Blood chemistry:
- •i. AST, ALT, and creatinine within the baseline range
- •ii. Total bilirubin within 50% deviation from the upper limit
- •iii. Serum electrolytes within the baseline range
- •iv. Other blood chemistry items within 25% deviation from the upper and lower limits of the baseline range
- •2.5.4. Urinalysis within the normal range
排除标准
- •Exclusion criteria for Stages 1 and 2:
- •1. Persons with fever (37.5°C or higher) on administration of the test vaccine
- •2. Persons with a clear history of food/drug-related anaphylaxis
- •3. Females (adolescents/adults) who are pregnant or have a positive urine beta-human chorionic gonadotrophin [beta-hCG] on the day of, or prior to, administration
- •4. Females currently lactating or breast-feeding
- •5. Persons with acute or chronic cardiovascular, pulmonary, hepatic, renal, or neurological condition, which in the opinion of the investigator may increase the risk of the subject from participating in the trial
- •6. Persons with a history of fever within 2 days after preventive administration with other types of vaccine, or those in whom symptoms have suggested systemic allergy
- •7. Persons with a history of convulsion
- •8. Persons with any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection. (No infectious disease testing will be conducted. HIV testing will not be done. Severe, suspected infectious diseases will be ruled out by investigators during physical examination/consultation, blood haematology/chemistry tests; although not conclusive of the causative agent). Additional oral confirmation: Subject informed the investigator that he/she has been tested positive for HIV/acquired immune deficiency virus (AIDS).
- •9. Persons with a history or tentative diagnosis of drug allergy
- •10. Persons with a history of or present drug/alcohol dependency
- •11. Persons who took any medication within 1 week before administration of this test vaccine (except for artemether/lumefantrine and dihydroartemisinin-piperaquine)
- •12. Persons to whom any live vaccine was administered within 4 weeks before administration of this test vaccine, or inactivated vaccine/toxoid was administered within 1 week
- •13. Persons who participated in another trial within 4 months before administration of this test vaccine
- •14. Persons in whom 200 ml of blood was collected (donation) within 1 month before administration of this test vaccine, or more than 400 ml of blood was collected within 3 months
- •15. Others who are not considered to be eligible by the investigator or those whose medical condition would, in the opinion of the investigator, make the subject unsuitable for the trial
研究者
相似试验
尚未招募
1 期
A randomized single-blind phase 1 clinical trial of OSKLIPO-0524, a liposomal cyclosporine, to assess pharmacokinetics and safety in Japanese healthy volunteersAcute myocardial infarctionJPRN-UMIN000018828Osaka University Hospital20
终止
4 期
Teriparatide for Pelvic Fracture HealingACTRN12614000059662Royal Brisbane and Women's Hospital40
尚未招募
2 期
INFINiTE-CV2 Phase IIa Trial: INterFeron type 1 Intra-Nasal gel Therapy for Early treatment of SARS-CoV2 (COVID-19)ACTRN12622000258752IntraVital100
招募中
1 期
A study to determine if a new vaccine safely generates good immune responses to protect adults in Kenya from Coronavirus DiseaseCOVID-19 DiseasePACTR202005681895696niversity of Oxford400
已完成
不适用
When reconstructing defects in the skull is it safer and more cost effective to use a patients own bone or a custom made titanium plateStrokeACTRN12612000353897Royal Perth Hospital64